According to FDA prescribing information, constipation occurs in 16-24% of Wegovy patients and 5-17% of Ozempic patients (dose-dependent), while diarrhea occurs in 11-30% of patients across products and doses
What sets it apart from Ipamorelin: Sermorelin was FDA-approved under the brand name Geref first as a diagnostic agent in 1990, then for GH deficiency in children in 1997 (Federal Register, PubMed)
Beyond these general guidelines, ideal candidates for GLP-1 therapy at Vital Health Medical Care include individuals who have struggled to achieve meaningful weight loss through diet and exercise alone, those with a personal or family history of metabolic conditions such as diabetes or cardiovascular disease, women navigating post-pregnancy weight challenges, and patients who have previously lost weight through other means but have experienced significant regain
Same dose, different volumes
Understanding Zepbound and the Intensity of Side Effects Zepbound contains tirzepatide , a dual incretin agonist that targets GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors